Valued at a market cap of $336 billion, AbbVie Inc. (ABBV) is a global biopharmaceutical company dedicated to developing ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

The Vanguard Health Care ETF has a large mix of healthcare holdings. Learn more about it and find out how to invest in it.

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

As the nation kicks off Black History Month, a look into the industry shows there is a significant lack of Black leaders.

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $183.9 which represents a slight increase of $8.25 or 4.70% from the prior close of $175.65. The stock opened at $187.3 and touched a low ...

ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

Argus Research analyst Jasper Hellweg maintained a Buy rating on AbbVie (ABBV – Research Report) on January 31. The company’s shares opened ...

In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...

AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing ...